Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    16503494 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Unknown  Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease
Condition: Graft vs Host Disease
Intervention: Drug: Alemtuzumab and Rituximab combination

Indicates status has not been verified in more than two years